Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:BYSI NASDAQ:ENTX NASDAQ:IZTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBYSIBeyondSpring$1.29-7.5%$1.61$1.18▼$3.44$57.36M0.4114,039 shs39,000 shsENTXEntera Bio$1.27+3.3%$1.21$0.91▼$3.22$60.55M1.54126,976 shs30,038 shsIZTCInvizyne Technologies$9.55-2.2%$9.15$8.50▼$23.00$59.71MN/A37,647 shs3,477 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-79.17%BYSIBeyondSpring+2.57%-8.22%-17.36%+7.31%-15.96%ENTXEntera Bio-2.38%+5.13%-3.91%-13.38%-39.41%IZTCInvizyne Technologies0.00%+1.46%-7.92%-4.52%-35.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBYSIBeyondSpring$1.29-7.5%$1.61$1.18▼$3.44$57.36M0.4114,039 shs39,000 shsENTXEntera Bio$1.27+3.3%$1.21$0.91▼$3.22$60.55M1.54126,976 shs30,038 shsIZTCInvizyne Technologies$9.55-2.2%$9.15$8.50▼$23.00$59.71MN/A37,647 shs3,477 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-79.17%BYSIBeyondSpring+2.57%-8.22%-17.36%+7.31%-15.96%ENTXEntera Bio-2.38%+5.13%-3.91%-13.38%-39.41%IZTCInvizyne Technologies0.00%+1.46%-7.92%-4.52%-35.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.75Reduce$0.50763.56% UpsideBYSIBeyondSpring 1.00SellN/AN/AENTXEntera Bio 2.00Hold$9.00608.66% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADAP, BYSI, ENTX, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.09N/AN/A$0.05 per share1.16BYSIBeyondSpring$1.75M30.31$0.11 per share12.28($0.74) per share-1.74ENTXEntera Bio$40K1,562.74N/AN/A$0.22 per share5.77IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%N/ABYSIBeyondSpring-$1.01M-$0.15N/AN/AN/AN/AN/A-14.00%N/AENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%N/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest ADAP, BYSI, ENTX, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29BYSIBeyondSpringN/A1.091.09ENTXEntera BioN/A7.937.93IZTCInvizyne TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%BYSIBeyondSpring40.29%ENTXEntera Bio14.11%IZTCInvizyne TechnologiesN/AInsider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%BYSIBeyondSpring29.31%ENTXEntera Bio10.38%IZTCInvizyne TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableENTXEntera Bio2049.22 million44.12 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/AADAP, BYSI, ENTX, and IZTC HeadlinesRecent News About These CompaniesInstitutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)February 13, 2025 | uk.finance.yahoo.comWhat’s in a Name: Out with Invizyne, In with eXoZymesFebruary 12, 2025 | genengnews.comGInvizyne Technologies rebrands as eXoZymes with new ticker EXOZFebruary 11, 2025 | msn.comInvizyne announces corporate name change to eXoZymesFebruary 11, 2025 | markets.businessinsider.comWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%February 4, 2025 | aaii.comAWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%January 30, 2025 | aaii.comAInvizyne technologies CEO Michael Heltzen buys $20,345 in stockJanuary 21, 2025 | msn.comInvizyne Technologies Inc trading resumesJanuary 1, 2025 | markets.businessinsider.comInvizyne Technologies Inc trading halted, volatility trading pauseJanuary 1, 2025 | markets.businessinsider.comMichael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) StockNovember 20, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAP, BYSI, ENTX, and IZTC Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.BeyondSpring NASDAQ:BYSI$1.29 -0.11 (-7.53%) Closing price 03:57 PM EasternExtended Trading$1.35 +0.06 (+4.57%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Entera Bio NASDAQ:ENTX$1.27 +0.04 (+3.25%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.01 (+1.10%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Invizyne Technologies NASDAQ:IZTC$9.55 -0.21 (-2.15%) As of 05/18/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
